Guidance for industry : IND exemptions for studies of lawfully marketed drug or biological products for the treatment of cancer.
| Other author | Center for Drug Evaluation and Research (U.S.) |
| Other author | Center for Biologics Evaluation and Research (U.S.) |
| Format | Electronic |
| Publication Info | Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, [2004] |
| Description | 1 online resource (8 p.) |
| Supplemental Content | https://purl.fdlp.gov/GPO/LPS116353 |
| Subjects |
| Portion of title | IND exemptions for studies of lawfully marketed drug or biological products for the treatment of cancer |
| General note | "Center for Biologics Evaluation and Research (CBER)." |
| General note | "Clinical medical." |
| General note | "Revision 1." |
| General note | "January 2004." |
| General note | GPO Cataloging Record Distribution Program (CRDP). |
| GPO item number | 0499-T (online) |
| Govt. docs number | HE 20.4702:IN 8/3 |
Availability
| Library | Location | Call Number | Status | Item Actions |
|---|---|---|---|---|
| Electronic Resources | Access Content Online | ✔ Available |